S Sean Tu
Biographic Data
| ID | 8449564 |
|---|---|
| NAME | S Sean Tu |
| GIVEN NAMES | S Sean |
| FAMILY NAME | Tu |
| SIGNATURE | TU S S |
| AFFILIATIONS | West Virginia University |
| ORCID | 0000-0003-0391-8186 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Tertiary Patents on Drugs Approved by the FDA
The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion
Using Trademarks to Ensure Completion of Postapproval Trials
This Viewpoint evaluates how using trademarks can support the US Food and Drug Administration’s mission to approve safe and effective medications
Mapping Intellectual Property Abuses in the Pharmaceutical Field
This Viewpoint details intellectual property abuses in the pharmaceutical industy involving patents, trademarks, copyrights, and trade secrets
Use of Track One Prioritized Examination for Pharmaceutical Patents
This study examines the use of the Track One prioritized patent examination program by pharmaceutical manufacturers from 2011 to 2022
No prominent works on this page.
Use of Track One Prioritized Examination for Pharmaceutical Patents
This study examines the use of the Track One prioritized patent examination program by pharmaceutical manufacturers from 2011 to 2022
Using Trademarks to Ensure Completion of Postapproval Trials
This Viewpoint evaluates how using trademarks can support the US Food and Drug Administration’s mission to approve safe and effective medications
Mapping Intellectual Property Abuses in the Pharmaceutical Field
This Viewpoint details intellectual property abuses in the pharmaceutical industy involving patents, trademarks, copyrights, and trade secrets
Tertiary Patents on Drugs Approved by the FDA
The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion
Business (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Intellectual Property and Patents (2 works) · Pharmaceutical Economics and Policy (2 works) · Science, Research, and Medicine (2 works) · Access to medicines (1 work) · Administration (probate law (1 work) · Biomedical Ethics and Regulation (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Cohort (1 work)